Crossmark

Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis

Crossref DOI link: https://doi.org/10.1186/s12967-023-04790-4

Published Online: 2023-12-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Jing-wen

Zou, Ying

Chen, Jun

Cui, Chen

Song, Jia

Yang, Meng-meng

Gao, Jing

Hu, Hui-qing

Xia, Long-qing

Wang, Li-ming

Lv, Xiao-yu

Chen, Li

Hou, Xin-guo
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82270845)

Double First Class University Plan (26010162914001)

Natural Science Foundation of Shandong Province (ZR2020ZD15)
License Information

Text and Data Mining valid from 2023-12-19

Version of Record valid from 2023-12-19
More Information

Article History

Received: 2 August 2023

Accepted: 8 December 2023

First Online: 19 December 2023

Declarations

:

: All animal experiments were approved by the Laboratory Animal Ethical and Welfare Committee of Shandong University Cheeloo College of Medicine (approval number: 23002).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below